About: Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.02 (+0.75%)
IMRX NASDAQ Immuneering Corp
Immuneering Corp share price
Atividade de preço de IMRX
Último preço
$ 4,020
Variação (24h)
0,03 USD (0,75%)
Volume
770.73K
Volume (média 4 sem.)
-
Abertura
$ 3,99
Variação do dia
$ 3,88 - $ 4,10
Fechamento anterior
$ 3,99
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
IMRX price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals